Dear Reader, Metaverse-related stocks have had a rocky start to 2022. But investment bank JPMorgan remains defiantly bullish. They predict US$1 trillion in annual revenues. And that the metaverse will ‘infiltrate every sector in some way in the coming years’. There’s one sector, though, getting very little attention. Not from Wall Street or the financial media. A decentralised metaverse is poised to be one of the biggest disruptions to the healthcare industry in 100 years. Medical VR, however, is still a niche topic…for now…which we believe gives us a distinct edge with this ASX-listed metaverse play. What they’re doing is taking the next leap in how we ‘see’ inside the human body. We can already do this to a degree with X-rays…CT scans…MRIs…ultrasounds, and PET scans. But what if you could shrink down to a fraction of the size of a single cell and walk into a human body like you were actually inside the body itself? You’re able to feel, look, and observe. This is a new metaverse-enabled way doctors and surgeons will be able to diagnose patients. Dr Shafi Ahmed is a surgeon, innovator, and medical futurist. A cancer surgeon at The Royal London and St Bartholomew’s hospitals, he’s been touted as the most-watched surgeon in history. That was after a virtual reality livestream of one of his operations went viral with a record number of viewers. ‘The Metaverse is the digital world’s next big thing which means for healthcare the possibilities are endless,’ Prof Ahmed says. As I say, this is an area where both retail and professional capital is yet to flood into. We think that’s about to change. And we want to get ahead of it…with this ASX stock. Click here to find out more. Regards, James Woodburn,
Publisher, Fat Tail Investment Research | 
